바로가기메뉴

본문 바로가기 주메뉴 바로가기
 

logo

메뉴

Browse Articles

The Role and Prospects of the Drosophila Model System in Human Rare Disease Research
Sung Dae Kim ; Andrew Kim ; Sarita Palacio ; Hyung-Lok Chung pp.15-28 https://doi.org/10.22742/JIG.2026.8.2.15
초록보기
Abstract

Drosophila melanogaster has served as one of the most powerful and versatile model organisms in biomedical research for over a century. Its high degree of genetic conservation with humans, with approximately 75% of human disease-associated genes having functional orthologs in the fly, combined with sophisticated genetic tools and a short generation time, makes it uniquely suited for investigating the mechanisms underlying human diseases. This review provides a comprehensive overview of the utility of Drosophila in rare disease research, highlighting its contributions across multiple disease categories, including neurological and neurodevelopmental disorders, metabolic and mitochondrial diseases, lysosomal storage disorders, sensory disorders, immunological conditions, and cancer. We discuss the technical advantages that make the fruit fly an ideal first-line model for functional genomics, including the GAL4/UAS system, CRISPR/Cas9 gene editing, and humanization strategies. Furthermore, we examine the inherent limitations of the fly model and the innovative approaches developed to overcome them, such as the integration of complementary model systems and the expression of human disease genes in flies. As rare diseases continue to pose significant diagnostic and therapeutic challenges, Drosophila remains an indispensable platform for elucidating disease mechanisms, validating patient-derived genetic variants, and identifying potential therapeutic targets.

Preimplantation Genetic Testing for Rare Monogenic Disease: A Female Reproductive Medicine Perspective on the Clinical Pathway
Dongsoo Park ; Haeryung Choi pp.29-35 https://doi.org/10.22742/JIG.2026.8.2.29
초록보기
Abstract

Preimplantation genetic testing for monogenic disorders (PGT-M) allows couples at high risk of transmitting a rare genetic disease to achieve an unaffected pregnancy while substantially reducing the likelihood of pregnancy termination after prenatal diagnosis. Although PGT-M is often presented as a molecular genetic technique, its clinical success also depends on reproductive variables: ovarian reserve, ovarian response to controlled stimulation, blastocyst yield, and obstetric management of the resulting pregnancy. This review follows the PGT-M pathway chronologically, from genetic diagnosis and pre-cycle workup through ovarian stimulation, embryo biopsy and genetic analysis, embryo transfer, and confirmatory prenatal diagnosis, and considers each step from the perspective of female reproductive medicine. Particular attention is given to the embryo attrition cascade that determines whether a transferable embryo will be available; the interpretation of outcomes per couple rather than per transfer; carrier states in which the pathogenic variant itself compromises ovarian function; and the counseling and regulatory framework applicable in Korea. PGT-M is best regarded not as a laboratory service but as a multidisciplinary program in which clinical genetics, the PGT laboratory, embryology, reproductive medicine, and obstetric care each contribute to the goal of a healthy live birth.

Genes Associated with Short Stature: An Update
초록보기
Abstract

Short stature is one of the most common reasons for referral to pediatric endocrinology clinics. In many children, no cause is identified, and they are classified as having idiopathic short stature (ISS). With recent advances in genetic testing, however, a growing number of these children are found to have monogenic defects. Linear growth is driven by chondrocyte proliferation, hypertrophy, and extracellular matrix production in the growth plate, and genetic variants that disrupt these processes impair growth. The affected mechanisms include endocrine signaling through the growth hormone (GH)–insulin-like growth factor I (IGF-I) axis; paracrine signaling and transcriptional regulation within the growth plate (SHOX, FGFR3, and NPR2); the cartilage extracellular matrix (ACAN); intracellular signaling (the RAS/MAPK pathway); fundamental cellular processes such as DNA replication and centrosome function; and genomic imprinting. Each mechanism is associated with a characteristic clinical pattern of birth size, body proportions, bone age, and biochemical findings. An accurate genetic diagnosis establishes the cause of growth failure, provides information on prognosis and associated risks, predicts the response to GH therapy, and enables genetic counseling. Mechanism-based therapies, such as C-type natriuretic peptide analogs for achondroplasia, are now entering clinical practice. In conclusion, the integration of clinical, biochemical, and genetic information according to the underlying cellular mechanisms is essential for the accurate diagnosis and management of children with short stature.

Beyond Copy-Number and Coding-Region Analysis: Resolving the Molecularly Unresolved Dystrophinopathy
초록보기
Abstract

Exon-level copy-number analysis followed by sequencing of all 79 DMD exons and their flanking intronic sequence achieves a cumulative sensitivity approaching 99%, and no current protocol reaches 100% sensitivity. In clinical series, however, approximately 2–5% of patients with convincing dystrophinopathy remain molecularly unresolved after such testing. This review addresses that residual group. The reasons for failure lie in the architecture of the locus: more than 99% of the 2.22 Mb locus is intronic, dosage-based assays cannot detect balanced rearrangements, and short reads resolve repeat-embedded breakpoints poorly. Published studies identify two main categories — deep intronic splice-altering variants and complex structural variants — but their relative proportions across populations remain uncertain. The evidence required to classify such a variant as causative depends on its class: transcript analysis is effectively indispensable for a novel deep intronic variant, whereas a rearrangement that directly disrupts coding exons may be resolved from breakpoint, phenotype and dystrophin findings. I set out how splicing evidence enters classification under the ClinGen Sequence Variant Interpretation Splicing Subgroup recommendations, a stage at which the same RNA result can inadvertently be counted twice. I also set out how the evidence for a balanced structural variant must be assembled where neither the copy-number nor the splicing scoring framework covers it, and propose a staged approach to the unresolved patient. Resolving the variant is a precondition for assessing genotype-dependent therapeutic eligibility and for variant-specific carrier testing in the family.

Monogenic Causes of Short Stature in Children Initially Diagnosed with Idiopathic Short Stature
초록보기
Abstract

Short stature is a common reason for referral to pediatric endocrinologists, yet its underlying cause often remains unidentified despite comprehensive clinical and biochemical evaluation. Recent advances in molecular genetic testing have revealed that a substantial proportion of children previously classified as having idiopathic short stature harbor pathogenic genetic variants. This review summarizes current genetic approaches to short stature and highlights major genes involved in growth plate regulation and the growth hormone–insulin-like growth factor 1 axis. Variants in genes such as SHOX, ACAN, NPR2, NPPC, IHH, and FGFR3 can disrupt growth plate chondrogenesis, whereas defects in GH1, GHR, IGF1, and IGF1R affect the GH–IGF-1 pathway. In addition, mild syndromic disorders, including those associated with PTPN11 variants, may present primarily as short stature. Phenotypic features, including body disproportion, bone age, biochemical findings, and family history, can provide important clues for selecting appropriate genetic tests. However, because many affected children lack distinctive clinical features, multigene panels and exome sequencing are increasingly important diagnostic tools. Establishing a molecular diagnosis may reduce unnecessary investigations, improve prognostic assessment, guide treatment decisions, and enable more individualized management. Genetic testing is therefore likely to become an increasingly integral component of the evaluation of children with unexplained short stature.

logo